NCT03991975

Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Acral Malignant Melanoma

Phase Ib Study to Evaluate the Safety and Efficacy of TQB2450 (PD-L1 Antibody) Combined With Anlotinib in Subjects With Advanced Acral Malignant Melanoma

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 42 (estimated)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

Conditions

• Advanced Acral Malignant Melanoma

Interventions

Type	Name	Description
DRUG	Anlotinib	a multi-target receptor tyrosine kinase inhibitor.
DRUG	TQB2450	TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

Timeline

• Start date: 2019-06-11
• Primary completion: 2020-03-31
• Completion: 2021-12-31
• First posted: 2019-06-19
• Last updated: 2019-10-30

Locations

1 site across 1 country: China